

PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

July 29, 2026

The meeting of the Pharmacy and Therapeutics (P&T) Committee of the North Carolina State Health Plan for Teachers and State Employees (the Plan) was called to order at 6:30 P.M. (EST) on Wednesday, July 29, 2026 via Zoom, accessible to the public through the Plan's website. Quorum was present.

MEMBERS PRESENT:

Ghassan Al-Sabbagh, MD, Gastroenterologist/Hepatologist, Gastroenterology & Hepatology Consultants
Jennifer Burch, PharmD, CDE, Owner, Central Compounding Center
David Konanc, MD, Neurologist, Raleigh Neurology Associates
W. Russell Laundon, PharmD, Pharmacist, Director of Pharmacy Integration, UNC Health Care
Garland Moeller, MD, Rheumatologist, CarolinaEast Internal Medicine
Stephen Hsieh, MD, Internal Medicine, High Rock Internal Medicine
Susan Moore, MD, Medical Oncologist/Hematologist, Carteret Cancer Center

MEMBERS ABSENT:

Timothy Ashley, MD, MPH Internal Medicine and Pediatrics, Duke Primary Care, Regional Director

PLAN & VENDOR STAFF:

Tom Friedman, Executive Director, State Health Plan
Caroline Smart, Deputy Executive Administrator, State Health Plan
Jenny Vogel, PharmD, Sr. Clinical Pharmacist, State Health Plan
Toni Prine, RPh, Director of Operations, Pharmacy Benefits, State Health Plan
Justin Wylie, Web Designer, State Health Plan
Renée Jarnigan, RPh, Clinical Advisor, CVS Health

Welcome

The Chairperson welcomed the Committee members and guests to the webinar and performed roll call. New Committee member, Dr. Susan Moore was introduced.

Conflict of Interest Statement

The Chairperson requested that the P&T Committee members review the agenda, which was distributed prior to the meeting, and to disclose any actual or potential conflicts of interest with any item on the agenda. No conflicts of interest were noted.

Old Business

The Chairperson asked the P&T Committee members to review the April 29, 2026 P&T Committee Meeting minutes, which were distributed prior to the meeting. There were no additions or corrections to the minutes, so they were approved as is.

Executive Director Update

Mr. Friedman provided members of the committee with a brief executive director update.

Formulary Updates

Ms. Jarnigan presented CVS Caremark's Quarterly Formulary Updates, effective October 1, 2026. This included additions to the formulary, utilization management criteria, product exclusions, and tier movements.

Ms. Jarnigan first identified one new molecular entity that is being removed from CVS's New-to-Market block and would be available as a covered product, along with the utilization management policies that go along with this product. The new molecular entity being added to the formulary is as follows: REVUFORJ.

The proposed utilization management for REVUFORJ includes Specialty Guideline Management (SGM) and Specialty Quantity Limits.

Ms. Jarnigan presented proposed formulary additions and line extensions. The five formulary additions are as follows: TYRUKO, EPYSQI, INVEGA HAFYERA, INVEGA TRINZA, and BRIUMVI. The two line extensions are as follows: ORLADEYO and KERENDIA. Dr. Vogel presented one add back: paroxetine mesylate 7.5mg capsules.

Dr. Konanc expressed opposition to the addition of TYRUKO to the formulary citing concerns which include the anti-JCV antibody testing causing false positives. Ms. Jarnigan and Dr. Vogel acknowledged these concerns and advised that members currently taking the reference product, TYSABRI, will be provided with continued access via prior use exemptions.

There was no additional opposition from the Committee members, so the formulary additions, add backs, and line extensions with any associated utilization management were approved as presented.

Ms. Jarnigan then explained that the Plan has a formulary exclusion exception process that is available to support Plan members who, per their provider, have a medically necessary reason to allow coverage of a formulary excluded drug.

Ms. Jarnigan then reviewed the following four products that will be excluded from the formulary starting on the effective date: TYSABRI*, SOLIRIS, ECOZA and ZTLIDO. Prior use exemptions will be provided to members currently utilizing a medication indicated with *, so these members will not need to change medications or go through the exceptions process to continue their current medication. All products being removed have therapeutic alternatives or generic equivalents that are covered as preferred products on the Plan's custom formulary.

There was no opposition from the Committee members, so the formulary exclusions were approved as presented.

Ms. Jarnigan identified one branded product: INVEGA SUSTENNA which will have a change in tier from non-preferred to preferred. Ms. Jarnigan then identified two branded products: ORENCIA and PERSERIS which will have a change in tier from preferred to non-preferred.

There was no opposition from the Committee members, so the formulary tier changes were approved as presented.

Adjourn

The Chairperson addressed the Committee by thanking them for their service and informed them that the next meeting would be held on September 30, 2026 at 6:30 P.M. via Zoom. The meeting was adjourned at approximately 7:15 P.M. (EST)

Jenny Vogel, Chair